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The complement system is an ancient part of the innate immune system important for 
both tissue homeostasis and host defense. However, bacteria like Staphylococcus 
aureus (SA) possess elaborative mechanisms for evading both the complement system 
and other parts of the immune system. One of these evasive mechanisms—important 
in causing chronic and therapy resistant infections—is the intracellular persistence in 
non-immune cells. The objective of our study was to investigate whether persistent 
intracellular SA infection of epidermal keratinocytes resulted in complement activation. 
Using fluorescence microscopy, we found that persistent SA, surviving intracellularly in 
keratinocytes, caused activation of the complement system with formation of the termi-
nal complement complex (TCC) at the cell surface. Skin samples from atopic dermatitis 
patients analyzed by bacterial culture and microscopy, demonstrated that SA coloniza-
tion was associated with the presence of intracellular bacteria and deposition of the TCC 
in epidermis in vivo. Complement activation on keratinocytes with persistent intracellular 
bacteria was found with sera deficient/depleted of the complement components C1q, 
Mannan-binding lectin, or complement factor B, demonstrating involvement of more than 
one complement activation pathway. Viable bacterial counts showed that complement 
activation at the cell surface initiated cellular responses that significantly reduced the 
intracellular bacterial burden. The use of an inhibitor of the extracellular signal-regulated 
kinase (ERK) abrogated the complement-induced reduction in intracellular bacterial load. 
These data bridge the roles of the complement system in tissue homeostasis and innate 
immunity and illustrate a novel mechanism by which the complement system combats 
persistent intracellular bacteria in epithelial cells.
Keywords: complement activation, membrane attack complex, classical pathway activation, intracellular 
infection, Staphylococcus aureus, atopic dermatitis, erk activation
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inTrODUcTiOn
Encompassing more than 30 proteins, the complement system 
is an ancient part of innate immunity (1), and it was originally 
described for its ability to complement phagocytes and antibod-
ies in microbial killing (2). The complement system combats 
infections by detection of microbial intruders followed by lysis or 
opsonization to facilitate microbial clearance. In tissue homeosta-
sis, the complement system plays a role as an intricate surveillance 
system by detecting altered host cells and facilitates clearance of 
dead or altered cells (1, 3). The different roles of the complement 
system are illustrated by complement deficiencies, which increase 
susceptibility to bacterial infections and/or autoimmune diseases, 
for example, C3 deficiency is generally associated with increased 
risk of bacterial infections, while deficiency of late complement 
component C5–C9 is associated with Neisseria infections in par-
ticular (4). Deficiency of C1q, which is important for clearance of 
apoptotic cells, is associated with systemic lupus erythematosus 
(5).
Staphylococcus aureus (SA) is an important human pathogen 
and a major cause of soft tissue, respiratory, bone, joint, and 
endovascular disorders (6, 7). SA is commonly associated with 
skin infections (8), for example in diseases like atopic dermatitis 
(AD) (9), a chronic inflammatory pruritic skin disease character-
ized by dry skin, pruritus, erythema, edema, scaling, excoriations, 
oozing, and lichenification (9). Disease flares of AD are associated 
with a microbial dysbiosis with abundance of SA (10, 11) sug-
gested to drive inflammation (12).
Staphylococcus aureus possess elaborative mechanisms for 
shielding against complement mediated killing (13) among its 
impressive arsenal of immune evasive strategies (14). One impor-
tant immune evasive mechanism by which SA is suggested to 
cause chronic and therapy-refractive infections is by intracellular 
survival in viable immune and non-immune host cells (15–21). 
SA can survive intracellularly in non-immune cells by switching 
phenotype to small colony variants (SCVs), a phenotype that does 
not invoke the same host responses in the cells as the wild type 
(9, 22, 23). This phenotype has been implicated in failure of anti-
biotic treatments (24). In AD, the dynamic interplay between SA 
and keratinocytes is proposed to result in a selection for bacteria 
that stimulate autophagy, thereby promoting degradation of the 
inflammasome and consequently promoting intracellular bacte-
rial survival (25).
Immune responses to extracellular SA infections are extensively 
studied, while the immune responses to persistent intracellular 
bacteria in non-professional immune cells like keratinocytes, 
despite its clinical importance, are poorly understood. Since 
persistent intracellular bacteria presumably result in changes of 
cellular homeostasis, we investigated whether persistent intracel-
lular SA in epidermal keratinocytes could alert the body’s intricate 
surveillance system, the complement system.
In the current study, we found that persistent intracellular 
bacteria surviving in epidermal keratinocytes promoted comple-
ment activation on the cell surface, this complement activation 
in turn initiated cellular responses that subsequently reduced 
the intracellular bacterial burden by an extracellular signal 
regulated kinase (ERK) dependent mechanism. To the best of 
our knowledge, this demonstrates for the first time a possible role 
of the complement system in combating persistent intracellular 
bacteria in non-phagocytic epithelial cells, thus, bridging the dual 




Rabbit polyclonal antibody against the C3d domain of human 
complement component 3 (C3), and rabbit polyclonal antibody 
against the C4c domain of human complement component 4 (C4) 
were purchased from Dako. Mouse monoclonal anti human C5b-9 
antibody directed against a neoepitope exposed on complement 
component 9 when incorporated into the terminal complement 
complex (TCC) is from BioPorto Diagnostics. Mouse monoclonal 
against human complement component 1q (C1q) is from Quidel. 
Rabbit polyclonal anti SA antibody is from Thermoscientific. 
Alexa fluor 488 goat anti rabbit IgG, Alexa fluor 594 goat anti 
mouse IgG and Alexa fluor 488 goat anti human from Molecular 
Probes. U0126, CRID-3, and AG1478 all used at concentration 
of (10 µM) from Tocris. Human purified C1q, Mannan-binding 
lectin (MBL), complement Factor B, C3, C6 proteins and sera 
depleted of C1q, C3, Factor B, C6 were from Quidel. The MBL 
deficient serum was obtained from an individual homozygous for 
the D (R52C, rs5030737) variant not able to activate the MBL 
dependent lectin pathway has been previously described (26). 
IdeS was purified as previously described (27) and was generously 
provided by Lars Björck and Inga-Maria Frick.
cell culture and inhibition assays
Keratinocytes were cultured as previously described (28) to 
near confluence in KGM medium (Lonza) with additional EGF 
(100 ng/ml). A day before confluence the medium was changed 
to KGM without EGF or insulin for 24 h to induce differentiation, 
and then changed to KGM without EGF, insulin or antibiotics for 
another 24 h before starting the infection experiments. For some 
experiments, confluent cells were treated for 48 h with the epider-
mal growth factor receptor (EGFR) inhibitor AG1478 (10 µM), 
and the medium was changed to KGM without EGF, insulin, 
or antibiotics overnight before starting the infection assays. For 
inhibition of ERK pathway signaling, medium containing 10 µM 
U0126 was used during complement activation on infected cells 
and until processing of cells for viable count. For inflammasome 
inhibition, medium containing 10  µM CP-456,773 (CRID-3) 
was used during complement activation and until processing of 
infected cells for viable counts. Both inhibitors were solubilized in 
DMSO and used at the same volume, and viability of cells follow-
ing treatment of both inhibitors was checked using microscopy 
and trypan blue staining (described below).
human skin samples
Atopic dermatitis patients aged 18 years or over, with AD verified 
by the UK refinement of the Hanifin and Rajka diagnostic criteria 
for AD (29, 30), were recruited from the Dermatology Clinic at 
Lund University Hospital, Lund, Sweden. Tissue biopsies from 
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AD lesional areas were taken from the skin of the patients. The 
participants gave informed consent complying with the Helsinki 
Declaration, and the Regional Ethics Examination Board of 
Lund, Sweden approved the study (Permit Numbers: 144/2010, 
317/2010, 82/2012).
immunohistochemistry of skin samples
The skin specimens were fixed in 4% formaldehyde, dehydrated, 
and embedded in paraffin. Slices (4 µm) were made and placed 
on superfrost plus slides (Thermofisher), followed by incubation 
at 60°C for 1 h. The slides were then processed in PT link module 
(Dako) for deparaffinization, dehydration, and epitope retrieval. 
EnVision FLEX Target Retrieval Solution, High pH (Dako) was 
used for this process at 97°C for 20 min. After Ag retrieval, slides 
were blocked for 1 h at room temperature using a blocking solu-
tion of TBS with 0.05% Tween 20 (TTBS), 1% BSA, and 5% serum 
from the same species as the secondary Abs were raised. The slides 
were then incubated overnight with primary Abs diluted 1:500 in 
the same blocking solution for 24 h. The slides were washed three 
times for 20 min in TTBS and incubated for 24 h with secondary 
Abs diluted 1:1,000 in the same blocking solution. The slides were 
then washed again three times and mounted with Prolong Gold 
antifade reagent mounting medium with DAPI (Invitrogen).
Bacterial culture and intracellular 
infection assay
The bacterial culture and intracellular infection experiments 
were performed essentially as previously described (31). An 
invasive clinical isolate of SA from atopic eczema (2957/13) and 
SA Newman were plated on Todd Hewitt with yeast (THY) agar 
and subsequently cultured overnight in THY broth, washed and 
used for experiments. Confluent keratinocytes in antibiotic free 
medium were infected with a multiplicity of infection (MOI) 
of 10–20 in 12 and 24-well plates, the plates were centrifuged 
at 1,000×g for 2  min to enhance uniformity of SA attachment 
to keratinocytes and incubated at 37°C for 3  h. Medium was 
then aspirated and changed to medium containing 100  µg/ml 
gentamicin for 90 min to kill extracellular bacteria. Medium con-
taining 10 µg/ml gentamicin was used throughout the remaining 
of the experiment.
For “intracellular SA present immediately after infection” 
keratinocytes were lysed for bacterial viable count after 90 min 
with 100  µg/ml gentamicin. For “persistent intracellular SA” 
keratinocytes were cultured for an additional 24  h in medium 
with 10 µg/ml gentamicin.
complement activation assay
Complement activation on keratinocytes was performed as 
described (28). Briefly, after 0 or 24  h in medium containing 
10  µg/ml gentamicin, infected, or control keratinocytes were 
incubated with 10% normal human serum (NHS), heat inacti-
vated human serum (HIS), depleted serum or medium for 3 h, as 
a source of complement. Cells were consequently washed in PBS 
and processing of keratinocytes for intracellular bacterial viable 
counts or fluorescence microscopy was done either directly or 
24 h after addition of the different sera.
intracellular Bacterial Viable counts
Keratinocytes were washed three times in ice cold PBS, scrapped, 
and lysed in 0.1% Triton X-100 in sterile water and vortexed 
several times. Lysates were serially diluted and plated on THY 
agar plates and colony forming units counts were performed the 
next day as described (31).
immunofluorescence (iF) Microscopy
Keratinocytes grown on inserts in 12 well plates were washed 
three times in ice cold PBS and fixed for 45 min in 4% PFA at room 
temperature. After two washes in PBS, the cells were blocked with 
5% goat serum and 5 mg/ml BSA at room temperature for 45 min 
in PBS with 0.05% Tween 20 (PBST). After blocking, incubation 
was performed with primary antibodies diluted in PBST with 
2.5% goat serum and 5 mg/ml BSA overnight in cold room under 
rotation. Next day, inserts were washed three times in PBST and 
incubated with secondary antibodies for 2–4 h at room tempera-
ture. The inserts were washed three times and mounted on slides 
using Prolong Gold antifade reagent mounting medium with 
DAPI (Invitrogen). Samples were visualized using a Nikon Ti-E 
microscope (Nikon) inverted fluorescence microscope equipped 
with Andor Neo/Zyla camera (Andor) and NIS elements advanced 
research software (Nikon) and a Plan Apochromat objective 
(Olympus). Fluorescence quantification was done by acquiring 
several images of each monolayer, covering around 10,000 cells, 
then analyzed with IntDen measurement (the product of Area 
and Mean Gray Value) using Fiji (32). No primary antibody 
controls are used as a reference for quantification.
Detection of apoptosis and necrosis
Apoptotic and necrotic cells were detected using an annexin 
V-FITC/Ethidium homodimer III (EtD-III) staining kit 
(Biotium), according to the manufacturer’s protocol. Briefly, 
control and infected cells were washed twice with PBS then incu-
bated with appropriate dilutions of annexin V-FITC and EtD-III 
in binding buffer for 30 min. Washed twice in binding buffer and 
fixed with 4% PFA containing 1.25 mM calcium chloride (CaCl2) 
at room temperature for 30  min, washed three times in PBS 
containing 1.25 mM CaCl2 and mounted on slides using Prolong 
Gold antifade reagent mounting medium with DAPI. Viability 
of infected cells treated with U0126 and CRID-3 was assessed 
using Trypan blue staining, briefly, cells were washed twice with 
PBS and incubated with trypsin for 10 min, cell suspension was 
then mixed 1:1 (v/v) with 0.4% trypan blue solution (Amresco) 
for 5 min, and viability was assessed using LUNA Automated Cell 
Counter (Logo Biosystems).
sDs-Page and immunoblotting
To examine the medium of control and infected cells for degra-
dation of complement components, medium was collected and 
centrifuged at 10,000  g for 10  min to remove cell debris, and 
supernatant was precipitated using 10% trichloroacetic acid. SDS-
PAGE and immunoblotting were performed on the precipitated 
medium according to the instructions from the manufacturer 
(Bio-Rad). After transfer of proteins from the polyacrylamide 
gels, the polyvinylidene difluoride (PVDF) membrane was fixed 
FigUre 1 | Experimental setup. An illustration of the two infection models used in this study, as well as the figures corresponding to the time points and analysis 
methods used. (a) Keratinocyte monolayers are infected with Staphylococcus aureus (SA) for 3 h, followed by killing of extracellular bacteria using 100 µg/ml 
Gentamicin for 90 min. At this time point, intracellular SA is referred to in the text as intracellular SA present immediately after infection. Incubation with normal 
human serum (NHS) at this time point leads to deposition of terminal complement complex (TCC) mostly on extracellular bacterial remnants. (B) Keratinocyte 
monolayers are infected with SA for 3 h, followed by killing of extracellular bacteria using 100 µg/ml Gentamicin for 90 min, keratinocytes are further incubated with 
10 µg/ml Gentamicin for 24 h, at this time point, intracellular SA is referred to in the text as persistent intracellular SA. Incubation with NHS at this time point leads to 
deposition of TCC on the surface of keratinocytes.
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for 30 min in TBS with 0.05% glutaraldehyde (Sigma-Aldrich) 
and blocked with 3% skimmed milk in TTBS for 30 min. PVDF 
membranes were then incubated overnight with primary antibody 
diluted in blocking solution. The following day, the membranes 
were incubated for 2 h with HRP-conjugated secondary antibody 
in blocking solution (Jackson Immunoresearch) and visualized 
by SuperSignal West Pico Chemiluminescent Substrate (Pierce). 
The PVDF membrane was stripped for 20 min in 0.2 mol/l gly-
cine (pH 2.5) and 1% SDS, washed twice with TTBS, and finally 
blocked before incubating overnight with a new antibody.
real-time Pcr
RNA was purified from control and infected cells using Direct-zol 
RNA miniprep (zymo research) according to the manufacturer 
instructions. cDNA was synthesized from 200  ng purified RNA 
using iScript cDNA synthesis kit (Bio-Rad), according to the 
instructions given by the manufacturer. RNA expression of comple-
ment components was analyzed with quantitative RT-PCR using iQ 
SYBR Green Supermix (Bio-Rad). Amplification was performed at 
55°C for 40 cycles in iCycler Thermal Cycler (Bio-Rad), and data 
were analyzed using iCycler iQ Optical System Software. RNA 
expression was normalized using GADPH as housekeeping gene.
statistical analysis
Student’s t-test was performed on log transformed values to 
compare different treatments in the case of viable counts. While 
for fluorescence quantification, Student’s t-test was performed 
on non-log transformed values. * denotes p <  0.05, ** denotes 
p < 0.01.
resUlTs
Persisting intracellular sa cause 
Deposition of complement Fragments on 
Primary Keratinocytes
To investigate if persistent intracellular survival of bacteria in 
non-immune cells results in complement activation at the cell 
surface, we set up a model of persisting intracellular infection with 
SA in epidermal keratinocytes. Primary epidermal keratinocytes 
were infected with an invasive strain of SA isolated from the skin 
of an AD patient. Cells were infected one day after confluence was 
reached, to ensure stable cell number throughout the experiment 
and to mimic the upper epidermal layer. After 3 h of infection, 
extracellular bacteria were killed using gentamicin (100 µg/ml) 
for 90 min, while intracellular SA remained viable (33). At this 
time point (T0), SA will be described as “intracellular SA present 
immediately after infection” in our model. Keratinocytes were 
then maintained in a medium containing gentamicin (10 µg/ml) 
for 24 h (T24). This time point where viable intracellular bacteria 
have persisted for more than 24 h we termed “persistent intracel-
lular SA.” The infection model is illustrated in Figure 1.
FigUre 2 | Keratinocytes with persistent intracellular Staphylococcus aureus (SA) activate the complement system on the cell surface. Immunofluorescence (IF) 
microscopy of primary keratinocytes infected with intracellular SA. (a) Keratinocytes were stained for complement activation fragments component 4 (C4), component 
3 (C3), and terminal complement complex (TCC) using normal human serum (NHS) or HIS as a source of complement, IF was quantified in the panel to the right.  
(B) Orthogonal view of Z-stacks of keratinocytes infected with intracellular SA (green) show deposition of TCC (red) when incubated with NHS but not HIS. (c) New 
medium was added to the cells after complement activation and collected after 24 h to monitor release of activation fragments deposited on cells, Western blots show 
higher signal of C3 and C4 degradation products in media of infected cells treated with NHS. (D) Keratinocytes with intracellular SA present immediately after infection 
(T0) or persistent intracellular SA (T24) were incubated with NHS, colocalization (yellow) of SA (green) and TCC (red) indicates complement deposition on extracellular 
SA, colocalization was quantified over three experiments and represented using Pearson’s correlation coefficient in the bar graph in the lower right corner.
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At T24 keratinocytes with persistent intracellular SA were 
incubated with 10% Normal human serum (NHS) as a source of 
complement. Using fluorescence microscopy, we found deposi-
tion of the TCC on keratinocytes with persistent intracellular 
SA (Figures 2A,B), this was accompanied by increased deposi-
tion of complement C3 and complement C4 on keratinocytes 
with persistent intracellular SA in comparison to non-infected 
keratinocytes (Figure 2A). Keratinocytes with persistent intracel-
lular SA incubated with heat-inactivated serum (HIS) lacking 
complement activity did not show deposition of C3, C4, or TCC 
(Figures 2A,B). Western blots of conditioned medium collected 
after 24 h of NHS treatment of keratinocytes with persistent intra-
cellular SA, showed increased C3 and C4 degradation in medium 
compared to controls (Figure 2C). The combined data of C3, C4, 
and TCC deposition, along with increased C3 and C4 degrada-
tion products in the medium, confirmed that keratinocytes with 
persistent intracellular SA activated the complement system.
To rule out participation of surviving extracellular SA, medium 
was plated both at T0 and T24, where no viable SA were found. To 
demonstrate that complement activation was not due to extracellular 
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bacterial remnants, NHS was added either to keratinocytes with 
intracellular SA present immediately after infection (T0) or to 
keratinocytes with persistent intracellular SA (T24) to compare the 
pattern of complement deposition. In keratinocytes with intracel-
lular SA present immediately after infection at T0, colocalization 
of TCC and SA was found by IF (Figure 2D) demonstrating that 
complement activation was associated with bacterial remnants 
present extracellularly. In contrast, only limited colocalization of 
complement and SA was found when NHS was added to keratino-
cytes with persistent intracellular SA at T24. This indicated that 
complement activation on keratinocytes with persistent intracel-
lular SA was not associated with extracellular bacterial remnants 
(Figure 2D). This was further substantiated using SA Newman, a 
strain defective in host cell invasion (34). We found colocalization 
of SA and TCC staining even at T24 (Figure S1 in Supplementary 
Material), indicating that colocalization of staining determines 
deposition of complement on extracellular bacterial remnants. 
Taken together, these data demonstrate that complement activa-
tion elicited by keratinocytes with persistent intracellular SA was 
not due to the mere presence of extracellular bacteria or bacterial 
remnants, but possibly involved cellular changes/responses due to 
the presence of the persistent intracellular bacteria.
activation of the complement system by 
Keratinocytes with Persistent Intracellular 
Bacteria involves More than One 
activation Pathway
By using sera depleted or deficient of essential complement com-
ponents, along with C3, C4, and TCC IF staining, we investigated 
the pathways involved in complement activation initiated by 
keratinocytes with persistent intracellular SA. We found that com-
plement C1q depleted, and MBL deficient sera, both activated the 
terminal pathway as shown by TCC staining (Figure 3A), and 
reconstitution of both C1q depleted and MBL deficient sera did not 
cause significant increase in TCC staining (Figure 3A). However, 
reconstitution of C1q depleted serum with C1q significantly 
increased C4 staining, unlike reconstitution of MBL deficient 
serum with MBL (Figure 3A). This indicated that the classical 
pathway is a major contributor to the C4 deposition. To investi-
gate the contribution of the alternative pathway, we used Factor 
B depleted serum. Factor B depleted serum activated the terminal 
pathway, and reconstitution with complement factor B did not 
significantly alter C4 or TCC staining (Figure  3A). However, 
unlike reconstitution of C1q depleted serum, reconstitution of 
Factor B depleted serum increased C3 deposition (Figure 3B), 
indicating a role for the alternative pathway in propagation of C3 
activation. As expected, C3 and C6 depleted sera did not give rise 
to TCC deposition on keratinocytes with persistent intracellular 
SA unless reconstituted (Figure  3A), and reconstitution of C3 
depleted serum increased C3 deposition (Figure 3B).
Since immune complexes are known to activate complement 
through the classical pathway (35), we assessed binding of 
natural IgG to keratinocytes with persistent intracellular SA by 
IF. We found increased IgG staining in keratinocytes with per-
sistent intracellular SA compared to non-infected keratinocytes 
when incubated with NHS. The IgG staining was significantly 
reduced if NHS was treated with IdeS, a specific streptococcal 
IgG degrading cysteine proteinase (27)—before incubation with 
keratinocytes (Figure 3C). IdeS treated NHS caused a decrease in 
C4 staining compared to non-treated NHS, but terminal pathway 
activation was not significantly reduced as shown by TCC stain-
ing (Figure 3D).
In aggregate, these data suggest a redundancy in activation of the 
complement system by keratinocytes with persistent intracellular 
SA, since C1q depleted, MBL deficient and Factor B depleted sera 
all gave rise to deposition of TCC. The classical pathway played 
a major role in C4 deposition as absence of C1q or degradation 
of IgG significantly decreased C4 staining, while the alternative 
pathway seemed to play a role in the propagation of C3 activation.
complement is activated in epidermis 
colonized with sa In Vivo
Atopic dermatitis is a chronic inflammatory skin disease and AD 
patients are commonly colonized with SA during AD flares (9). 
To investigate if complement activation takes place on epidermal 
keratinocytes infected with intracellular SA in vivo, we double-
stained with IF the epidermis of five AD patients with or without 
SA colonization and three healthy controls for SA and TCC. We 
found increased staining of TCC in SA colonized AD epidermis 
both in comparison to healthy controls and AD epidermis not 
colonized with SA (Figure 4A), demonstrating that SA coloniza-
tion was associated with complement activation in AD. In some 
instances, the staining of TCC and SA co-localized, suggesting 
TCC formation on extracellular SA (arrow heads in inset, 
Figure 4A). In other instances, we found a similar pattern as in 
our model with persistent intracellular SA in keratinocytes where 
TCC and SA did not colocalize, suggesting that intracellular SA 
in epidermal keratinocytes may contribute to complement activa-
tion (Figure 4A).
To substantiate the presence of intracellular SA in AD skin, 
SA-colonized AD skin (verified by growth of SA colonies on agar) 
was incubated overnight in medium with or without gentamicin 
(10 µg/ml) to kill extracellular SA, and then incubated in 10% 
NHS as a source of complement before processing tissue for IF. 
Intracellular presence of SA in AD epidermis was demonstrated 
by the positive staining of SA in AD skin after gentamicin treat-
ment (Figure 4B, arrow head in inset). The SA staining in the 
gentamicin treated skin did not strictly co-localize with TCC 
staining (Figure 4B), thus, displaying a similar staining pattern 
as found in our model of keratinocytes with persistent intracel-
lular SA. Non-gentamicin treated skin, in which extracellular and 
intracellular SA was present, demonstrated more generalized co-
localization of SA and TCC compared to gentamicin treated skin 
(Figure 4B, arrows in inset), as well as more SA and TCC staining 
in general (Figure 4B). These data indicate that intracellular SA is 
present in keratinocytes of SA colonized AD epidermis and could 
possibly play a role in activating complement in vivo.
complement activation Takes Place on 
Viable Keratinocytes
To investigate whether the observed complement activation was 
due to cell death, we used an apoptosis and necrosis quantification 
FigUre 3 | Pathways involved in complement activation induced by Keratinocytes with persistent intracellular Staphylococcus aureus. (a) Infected keratinocytes 
were incubated with depleted or deficient sera along with respective reconstitution proteins as a source of complement, then stained for component 4 (C4) and 
terminal complement complex (TCC). Immunofluorescence (IF) representative images are shown in the left panel along with quantification on the right. (B) IF of C3 
was quantified in different depleted and reconstituted sera to confirm participation of the alternative pathway. (c) IF of IgG was quantified using anti human IgG 
antibodies, binding of IgG was found to be increased in infected keratinocytes incubated with normal human serum (NHS) or HIS. Treatment of NHS with IdeS 
significantly decreased IgG binding. (D) IF C4 and TCC were quantified in infected keratinocytes incubated with NHS or IdeS treated NHS.
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kit, that employs annexin V binding to the membrane of apoptotic 
cells (36), and EtD-III to selectively stain necrotic cells (37). We 
found no significant difference in apoptosis and necrosis between 
keratinocytes with or without persistent intracellular SA in our 
experimental model (Figure  5A). Moreover, morphological 
hallmarks of apoptosis (cell shrinkage and nuclear fragmentation) 
were absent in the keratinocytes with persistent intracellular SA 
(Figure 5A). This indicated that complement activation occurs 
in viable keratinocytes. When increasing the MOI three times 
compared to the MOI used in our study, there was significant 
FigUre 4 | Complement activation in Staphylococcus aureus (SA) colonized 
atopic dermatitis (AD) epidermis. Representative immunofluorescence images 
of skin samples from healthy and AD patients stained for SA and terminal 
complement complex (TCC). (a) SA colonized AD epidermis shows an 
increase in TCC staining near infected keratinocytes, in comparison to healthy 
epidermis, or AD epidermis not colonized with SA. SA and TCC staining 
colocalized in some instances (arrow heads in inset), indicating deposition on 
extracellular bacteria, while in other instances it did not, suggesting 
intracellular localization of SA. (B) To confirm intracellular presence of SA, 
SA-infected AD epidermis was treated with gentamicin for 24 h to kill 
extracellular SA or left untreated, then incubated with normal human serum 
(NHS). Gentamicin treated epidermis showed SA staining, suggesting 
presence of intracellular SA (arrow heads in inset), while TCC staining did not 
colocalize with SA to the degree found in non-treated epidermis, which 
showed increased SA and TCC colocalization (arrows in inset). A no primary 
control is used for comparison of staining. Asterixis represent the apical side 
of the epidermis, which is not included in the investigation behind the dashed 
line due to the high unspecific binding of keratin.
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apoptosis and necrosis in the monolayer (Figure 5A), in accord-
ance with other studies showing that bacterial load affects the 
cellular survival upon infection (38).
complement activation is Found When 
Persistent intracellular sa Were Present in 
scVs
In our model of persistent intracellular SA, we did not observe 
SCVs commonly implicated in chronic and antibiotic resistant 
SA infections (20). However, SA survived for up to 7  days in 
viable keratinocytes (Figure 5B), but after 7 days it was mostly 
in the form of SCVs, as judged by the morphology of the 
colonies on agar. Increased apoptosis and necrosis (Figure S2A 
in Supplementary Material) was observed 7 days after the time 
the cells were infected, both in keratinocytes with and without 
persistent intracellular SA, probably due to the normal life cycle of 
the confluent culture of primary keratinocytes. At the time point 
where SCVs were present intracellularly, incubation with NHS 
still resulted in increased TCC deposition in cells with persistent 
intracellular SA in comparison to controls with no intracellular 
bacteria (Figure S2B in Supplementary Material). This demon-
strated that persistent intracellular SA promoted complement 
activation in viable keratinocytes even when the intracellular bac-
teria were present as SCVs after prolonged intracellular survival.
complement activation leads to a 
reduction of Persistent intracellular sa
By viable count, we found that NHS treatment of keratinocytes 
with persistent intracellular SA significantly reduced the number 
of viable intracellular SA compared to HIS or non-treated cells 
by more than 60% in absolute colony counts (Figure 6B). This 
reduction of intracellular bacteria was seen 24 h after NHS treat-
ment. No reduction in intracellular bacteria was found directly 
after NHS treatment (Figure 6A), suggesting that bacterial clear-
ance required a cellular response elicited by NHS treatment.
To pinpoint the role of complement pathways and compo-
nents important in reducing intracellular bacterial load by NHS 
treatment, we used depleted and deficient sera of complement 
components, along with reconstituted sera. We found that recon-
stitution of C1q, C3 and Factor B depleted sera, but not MBL 
deficient serum led to a significant decrease in intracellular viable 
counts (Figure 6B). This demonstrated that complement activa-
tion was responsible for the observed reduction in intracellular 
bacterial load following NHS treatment, and that this effect was 
mediated by both the classical and alternative pathways but not 
the MBL pathway. IdeS treatment of NHS did not influence the 
reduction in intracellular bacteria, indicating that IgG antibodies 
did not play a major role in the reduction of persistent intracellular 
SA following complement activation (Figure 6B). Reconstitution 
of C5 and C6 depleted sera also led to reduction of persistent 
intracellular SA; however, this was not statistically significant, 
demonstrating that TCC was not majorly or solely involved in the 
reduction of intracellular bacteria, but that activation fragments 
in particular of C3, played a role in this regard.
Only cell Mediated complement 
activation leads to reduction in 
intracellular Bacterial load
We then investigated whether only cell mediated complement 
activation and not complement activation caused by bacterial 
remnants reduced the intracellular bacterial survival. We have 
previously demonstrated that EGFR inhibition led to—unde-
fined—cellular responses that cause cell mediated complement 
activation on the surface of epidermal keratinocytes treated 
with NHS (28). Thus, EGFR inhibited cells represent a model 
of keratinocyte mediated complement activation independent 
of bacteria or extracellular bacterial remnants. Accordingly, we 
compared intracellular SA viability in cells with intracellular SA 
FigUre 5 | Complement activation takes place on viable keratinocytes. (a) Immunofluorescence microscopy of control and infected keratinocytes shows no 
significant difference in apoptotic cells stained with Annexin V (green), and necrotic cells with EthD-III (red). A representative experiment was quantified in the bar 
graph to the right, treatment with normal human serum (NHS)/HIS did not show any significant difference. Insets show a close up of apoptotic and necrotic cells. 
Arrow heads point to Staphylococcus aureus DNA stained with EthD-III. Light microscopy shows intact monolayers of control and infected primary keratinocytes.  
A higher multiplicity of infection (MOI) induced extensive apoptosis and necrosis in the monolayers and was used as a positive control. (B) Keratinocytes infected for 
7 days were found to harbor intracellular bacteria, both keratinocytes and bacteria (arrow head) shown in the image are thought to be viable since they did not stain 
for the apoptosis or necrosis markers.
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present immediately after infection where complement activation 
takes place on bacterial remnants at T0 (Figure 2D), to EGFR-
inhibited cells also with intracellular SA present immediately after 
infection at T0, where the later activate complement both on 
their surface and on the bacterial remnants. We found that 24 h 
after NHS treatment, EGFR-inhibited cells had significantly less 
intracellular SA compared to HIS treated cells, unlike non-EGFR-
inhibited cells where no significant difference was seen (Figure 
S3 in Supplementary Material). This demonstrated that only 
keratinocyte-mediated complement activation, and not comple-
ment activation due to extracellular bacterial remnants, caused a 
reduction in the intracellular bacterial load.
FigUre 6 | Keratinocytes actively cleared intracellular Staphylococcus aureus (SA) after complement activation. (a) Keratinocytes infected with SA for 24 h were 
treated with normal human serum (NHS)/HIS, then lysed and intracellular bacteria plated, either directly after complement activation (T0) or after 24 h (T24).  
(B) Depleted/deficient sera along with the respective reconstitution proteins were used to underline the complement components essential for bacterial clearance. 
(c) The inflammasome inhibitor CRID-3 was used to investigate if the effect seen is related to inflammasome activation, the effect of NHS on viable counts was not 
changed. (D) Treating infected keratinocytes with the ERK inhibitor U0126 abrogated the effect of NHS on bacterial viable counts. Each gray dot represents a 
keratinocyte monolayer. Black bars represent the average, and error bars represent standard deviation. * p < 0.05, ** p < 0.01. Each experiment was repeated at 
least three times, experiments using depleted sera are independent and are only compared with the respective reconstituted serum.
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complement Mediated reduction of 
Persistent intracellular Bacteria is a 
cellular response Dependent on Mitogen-
activated Protein Kinase (MaPK) Pathway
To investigate the role of the inflammasome in the killing of 
persistent intracellular bacteria, we inhibited inflammasome 
activation in infected keratinocytes using the potent inhibitor 
of nucleotide-binding domain, leucine-rich-containing family, 
pyrin domain-containing-3 (NLRP3) inflammasome assembly, 
CRID-3 (39). CRID-3 inhibited interleukin-1 beta release from 
keratinocytes with persistent intracellular SA, demonstrating that 
CRID-3 inhibited inflammasome assembly in these cells (Figure 
S4A in Supplementary Material). However, CRID-3 treatment 
did not influence the number of persistent intracellular SA after 
complement activation (Figure  6C), demonstrating that the 
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complement mediated reduction in persistent intracellular SA was 
not related to inflammasome activation.
To investigate whether the reduction of intracellular 
bacterial load was related to increased autophagy, we used 
fluorescence microscopy to detect microtubule-associated 
protein 1A/1B-light chain 3 (LC3) and lysosomal-associated 
membrane protein 1 (LAMP-1) and examined the expression 
of autophagy-related genes Atg5 and beclin-1 using qPCR. We 
found no significant difference in LC3 or LAMP-1 staining, 
nor in Atg 5 and beclin-1 expression when comparing cells 
with intracellular SA treated with NHS or HIS (Figures S4B,C 
in Supplementary Material). This indicated that the bacterial 
clearance induced by complement activation was not related to 
increased autophagy.
However, treatment of keratinocytes harboring persistent 
intracellular SA with U0126, an inhibitor of the MAPKs/extra-
cellular signal-regulated kinases (ERK), abrogated the reduction 
in the intracellular bacterial load mediated by complement acti-
vation (Figure 6D), demonstrating that complement activation 
reduced intracellular SA by an active cellular process mediated 
through the MAPK pathway signaling. The effect of U0126 
was not due to reduced expression of antimicrobial peptides 
(AMPs), since we tested human β-defensin 2 (hBD-2), RNase 
7, and human β-defensin 3 (hBD-3) and none were induced 
by complement activation on cells with persistent intracellular 
bacteria (expression of hBD-2 was not detected) (Figure S4D 
in Supplementary Material). Furthermore, control experiments 
using trypan blue staining demonstrated that 10 µM of U0126 or 
CRID-3 treatment did not affect viability of infected cells (data 
not shown).
DiscUssiOn
The adept skin pathogen SA has been shown to persist in 
keratinocytes in vitro and in vivo (19, 20, 40, 41). The intracel-
lular reservoir is suggested to contribute to dissemination, recur-
rence and antibiotic resistance (16, 42). While host responses 
to extracellular SA infections are extensively studied, the host 
response to intracellular bacterial persistence in non-professional 
immune cells like keratinocytes is poorly understood. Since per-
sistent intracellular bacterial survival of SA likely affects tissue 
homeostasis, and the complement system is a pivotal surveillance 
system of tissue homeostasis, we investigated whether persistent 
intracellular SA in viable epidermal keratinocytes promoted 
complement activation. To this end, we set up a model of persis-
tent intracellular SA where intracellular bacteria persisted more 
than 24 h after infection.
We found that primary epidermal keratinocytes with persistent 
intracellular SA activated the complement system. In our model 
of persistent intracellular SA, where extracellular bacteria were 
killed and removed, we found no co-localization between detect-
able bacteria/bacterial remnants and deposition of complement, 
demonstrating that the observed complement activation was not 
mediated by bacteria/bacterial remnants.
Complement activation takes place on apoptotic and necrotic 
cells (20, 21). Although keratinocytes have been found to be resil-
ient to SA (18), previous studies have also demonstrated that SA 
infected keratinocytes can undergo apoptosis after internalization 
of SA (19). However, we found that complement deposition on 
keratinocytes with persistent intracellular SA in our experimental 
model was not associated with increased apoptosis or necrosis. 
Thus, we hypothesize that the persistent presence of viable intra-
cellular bacteria may trigger cellular response(s) or change(s) in 
cellular homeostasis unrelated to apoptosis or necrosis in a way 
that leads to complement activation.
Complement activation was performed with sera deficient 
or depleted of essential complement components to identify 
the complement pathway responsible for complement activa-
tion triggered by the presence of persistent intracellular SA. 
Surprisingly, complement activation was found with both C1q 
and factor B depleted sera as well as with MBL deficient serum, 
judged by deposition of C3, C4, and TCC. Experiments with 
sera where IgG was degraded still demonstrated complement 
activation, ruling out a major role of IgG even for the C1q-
mediated complement activation. This demonstrates that other 
mechanisms are responsible for the C1q-mediated complement 
activation like direct binding of C1q and/or natural IgM antibod-
ies to the infected cells (43). Furthermore, a contribution of other 
recognition molecules like the ficolins and collectins in the lectin 
pathway could also blur the picture (44). Nonetheless, our data 
clearly indicate that more than one pathway was involved in the 
observed complement activation on keratinocytes with persistent 
intracellular SA.
Apart from their role in forming a physical barrier, keratino-
cytes are active participants in the immune response to skin 
infections, through production of AMPs, complement compo-
nents, and chemotactic factors (45, 46). Indeed, we previously 
found that saliva treatment caused reduction of intracellular SA 
in infected keratinocytes (31), demonstrating that keratinocytes 
can respond to external stimuli by actively reducing the number 
of intracellular bacteria. Consequently, we tested whether the 
complement activation promoted clearance of persistent intracel-
lular SA.
Complement activation on keratinocytes with persistent 
intracellular SA did indeed lead to a reduction in the intracellu-
lar bacterial load. Sera depleted of C1q, C3, and factor B, all had 
significantly decreased the number of intracellular bacteria after 
reconstitution, while this was not the case for MBL deficient 
serum. Thus, it seems likely that the complement activation 
required to decrease the load of intracellular persistent bacte-
ria, was initiated by the classical pathway and amplified by the 
alternative pathway. No effect on the number of intracellular 
bacteria was seen directly after complement activation. This was 
not surprising since the persistent bacteria were intracellular 
while complement activation took place extracellularly, and also 
since SA is resistant to direct killing by complement activation 
(13). Instead, complement activation reduced the number of 
intracellular bacteria through a cellular response mediated by 
activated complement components. Complement components 
have previously been shown to activate keratinocytes either 
through binding to complement receptors (47) or through sub-
lytic TCC insertion (48), and we have previously demonstrated 
that keratinocytes can reduce the intracellular bacterial load 
after stimulation (31).
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The mechanisms by which keratinocytes reduce the intra-
cellular bacterial load are not well understood, but inflam-
masome assembly and subsequent caspase-1 dependent cell 
death or pyroptosis, as well as autophagy, have been suggested 
as mechanisms to limit survival of intracellular pathogens (49). 
However, inhibition of inflammasome assembly did not reduce 
the number of persistent intracellular SA, and complement 
activation did not induce autophagy. We previously found 
that saliva (as a model of wound licking) reduced the num-
ber of intracellular bacteria in keratinocytes, paralleled with 
expression of AMPs, especially human β-defensin-3 (31). Yet, 
complement activation did not induce expression of human 
β-defensin-3 or other AMPs. The MAPK pathway is important 
for regulating immune functions in keratinocytes (50, 51). 
Inhibition of MAPK dependent ERK activation abrogated 
the complement mediated reduction of persistent intracellular 
SA, thus demonstrating that the MAPK pathway is involved 
in complement mediated cellular responses which reduce the 
load of persistent intracellular SA.
Although cells with intracellular bacteria have been dem-
onstrated to undergo autophagy, apoptosis and pyroptosis 
(52), keratinocytes have been found to be resilient to SA (53). 
Nevertheless, our data demonstrate that keratinocytes seemed to 
adjust to the persistent intracellular SA with subtle and not yet 
identified changes that in turn promote complement activation, 
not unlike what is seen after EGFR inhibition (28). To understand 
the role of the complement system in the dynamic interplay 
between bacteria and keratinocytes in chronic and therapy resist-
ant infections, the cellular changes or adaptions to the persistent 
intracellular bacteria that result in complement activation should 
be further delineated.
The complement system is known to have important roles 
in the skin. Locally synthesized complement components in 
the skin play a role in inflammatory skin diseases (54, 55), and 
complement deficiencies are associated with pyogenic skin infec-
tions (4). Blocking of certain complement proteins alters the skin 
microbiome (56). Since plasma exudation commonly follows 
epidermal inflammation, we hypothesize that complement 
activation induced by keratinocytes with persistent intracellular 
bacteria could maintain an inflammatory response after clearing 
the initial insult while at the same time limiting the number 
of intracellular bacteria. This could be relevant in AD patients 
commonly infected with SA during AD flares. Although the 
contribution of intracellular SA in AD has not been examined, 
and is beyond the scope of this work, our in vivo data suggest 
that intracellular SA in the epidermis could lead to activation of 
complement, thereby contributing to the inflammation found in 
SA-colonized AD skin. In this regard, it is worth noting that anti-
staphylococcal therapies may play a role in severe, superinfected 
AD (57). Although there is no clear evidence for a clinical benefit 
of antibiotic therapies in non-infected AD, short courses of sys-
temic antibiotics in more extensive forms of superinfected AD 
might be needed (9, 57, 58). If complement activation induced by 
persistent intracellular SA plays a role in the inflammation seen in 
AD flares, it would probably be beneficial if the chosen antibiotic 
treatment targets not only extracellular bacteria but also the 
persistent intracellular SA.
The complement system is seen as an important surveil-
lance system for maintaining tissue homeostasis. Our study 
demonstrates that keratinocytes with persistent intracellular 
SA activate the complement system resulting in reduction of 
the intracellular bacterial load. This ties together the known 
functions of the complement system in host defense and tissue 
homeostasis and demonstrates a novel role of the complement 
system in combating bacteria like SA, otherwise resistant to 
complement mediated killing, when present intracellularly in 
non-phagocytic cells.
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